ARTICLE | Company News
Innovimmune autoimmune, inflammation news
June 18, 2012 7:00 AM UTC
Newco Innovimmune received a $600,000 Advanced Technology Small Business Innovation Research (SBIR) grant from NIH to develop the company's INV-88 product portfolio of oral small molecule macrophage migration inhibitory factor (MIF) inhibitors to treat rheumatoid arthritis (RA). The company said it is also developing the INV-88 portfolio, which is in discovery, for multiple sclerosis (MS), Alzheimer's disease (AD), Type I and Type II diabetes, obesity, lupus, asthma, Crohn's disease, ulcerative colitis (UC), cancer and age-related macular degeneration (AMD). ...